Galcanezumab-gnlm 100 mg/ML [Emgality]
RxNorm 2170612
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 2170612 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: galcanezumab-gnlm 100 mg/ML [Emgality].
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
SBDCPrescribable
Semantic Branded Drug Component (SBDC):
Galcanezumab-gnlm 100 mg/ML [Emgality]
(Atom ID: 11421131)
Patient Education
Galcanezumab-gnlm Injection
Galcanezumab-gnlm injection is used to help prevent migraine headaches (severe, throbbing headaches that sometimes are accompanied by nausea and sensitivity to sound or light). It is also used to treat the symptoms of a cluster headache (severe headaches usually on one side of the head or around one eye). Galcanezumab-gnlm injection is in a class of medications called monoclonal antibodies. It works by blocking the action of a certain natural substance in the body that causes migraine headaches.
[Learn More]
* Please review the disclaimer below.